Financials in USD. Standardized financial statements.
A compact view of how Mersana Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $40.50M | $36.85M | $26.58M | $43,000 | $828,000 | $42.12M | $10.59M | $17.55M | $25.17M | $10.36M |
| Revenue Growth? | +9.9% | +38.7% | +61716.3% | -94.8% | -98.0% | +297.6% | -39.6% | -30.3% | +143.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $67.04M | $0 | $59.91M | $928,000 | $32.01M | $21.35M |
| Gross Profit? | $40.50M | $36.85M | $26.58M | $43,000 | -$66.21M | $42.12M | -$49.32M | $16.62M | -$6.84M | -$10.99M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | -7996.1% | +100.0% | -465.6% | +94.7% | -27.2% | -106.1% |
| Operating Expenses? | $113.83M | $207.81M | $230.35M | $168.90M | $88.94M | $72.32M | $76.25M | $57.16M | $38.99M | $26.70M |
| Operating Income? | -$73.34M | -$170.96M | -$203.77M | -$168.86M | -$155.15M | -$30.20M | -$65.66M | -$39.62M | -$13.82M | -$16.34M |
| EBITDA? | -$63.27M | -$166.08M | -$199.96M | -$167.94M | -$87.10M | -$26.73M | -$63.00M | -$37.78M | -$13.17M | -$16.04M |
| Income Before Tax | -$68.77M | -$171.67M | -$204.21M | -$170.06M | -$88.05M | -$28.21M | -$64.26M | -$38.71M | -$13.70M | -$16.43M |
| Income Tax Expense | $418,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$2,000 |
| Net Income? | -$69.19M | -$171.67M | -$204.21M | -$170.06M | -$88.05M | -$28.21M | -$64.26M | -$38.71M | -$13.70M | -$16.43M |
| EPS? | $-14.12 | $-36.96 | $-54.51 | $-60.24 | $-35.80 | $-16.25 | $-69.75 | $-43.00 | $-19.58 | $-23.48 |
| Diluted EPS? | $-14.12 | $-36.96 | $-54.51 | $-60.24 | $-35.80 | $-16.21 | $-69.75 | $-42.95 | $-19.58 | $-23.48 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality